ORLEANS, Ontario, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc
(“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based
drug discovery and development has announced that it is in process of filing a patent application for its PPP001 drug
product. Tetra’s research has led to a significant discovery that allows for patent protection.
“This patent application, if granted, would provide Tetra with full protection of its PPP001 prescription drug
product. This will put PPP001 in the same category as any other innovative prescription drug,” said Dr. Guy Chamberland, CEO
and CSO of Tetra Bio-Pharma. “We recognize the inherent value of our intellectual property and the necessity to seek appropriate
patents, to the extent possible, to protect our shareholders' investments in the Company.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery
and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel
prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the
development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products
containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra
Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio
pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies
of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that
address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future
(including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements.
Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect",
"anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these
words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are
beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from
those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from
current expectations include, among other things, without limitation, the failure for the Company to achieve patent protection
for its PPP001 drug product, the inability of the Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research
and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein,
the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing
and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record
on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that
could cause actual results or events to differ materially from those described in forward-looking statements, there may be other
factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on
forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news
release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new
information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com
![TETRA_150.jpg](https://resource.globenewswire.com/media/2c4e6b53-8422-4ab8-b82e-bdcf305f6c17/small/tetra-150-jpg.jpg)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2NDAjNzQ2MTkzMw==)